Temporary hypocalcemia induced by cetuximab sarotalocan without hypomagnesemia in a patient with hypoparathyroidism: a novel case report
{{output}}
Background: Cetuximab sarotalocan, which utilizes the light-activatable dye IRDye700Dx conjugated with cetuximab, is a first-in-class drug based on photoimmunotherapy for treating recurrent head and neck squamous cell carcinoma. ... ...
